LegalJun 8, 2026, 08:46 AM
CorMedix Wins Patent Litigation Against Nexus Pharmaceuticals
AI Summary
CorMedix Inc. has secured a significant legal victory as the U.S. Court of Appeals for the Federal Circuit affirmed a lower court's judgment. The ruling confirms that Nexus Pharmaceuticals Inc.'s generic minocycline product infringes two of CorMedix's patents and rejects Nexus's challenge to the patents' validity. This decision upholds a permanent injunction against Nexus, preventing them from marketing their generic product until patent expiration, and validates the intellectual property protecting CorMedix's MINOCIN® for Injection.
Key Highlights
- CorMedix Inc. announced a victory in patent litigation against Nexus Pharmaceuticals.
- The U.S. Court of Appeals for the Federal Circuit affirmed a lower court ruling.
- The ruling found Nexus' generic minocycline product infringed two CorMedix patents.
- Nexus' invalidity challenge was rejected by the appeals court.
- A permanent injunction barring Nexus from marketing its generic product remains in place.
- The patents protect CorMedix's MINOCIN® for Injection, an intravenous minocycline antibiotic.
Price Impact
More from CRMD